Lutetium oxodotreotide ((177)Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

BACKGROUND: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a heterogenous group of tumors. Findings from the phase III NETTER-1 trial showed that treatment of unresectable/metastatic progressive gastrointestinal (GI) NETs with (177)Lu-Dotatate resulted in a significant improvement...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith-Palmer, J., Leeuwenkamp, O. R., Virk, J., Reed, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786468/
https://www.ncbi.nlm.nih.gov/pubmed/33402120
http://dx.doi.org/10.1186/s12885-020-07710-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786468/
https://www.ncbi.nlm.nih.gov/pubmed/33402120
http://dx.doi.org/10.1186/s12885-020-07710-7

Ejemplares similares